Proactively planning AI implementation with regulatory compliance in mind
The use of digital tools, including artificial intelligence, is rising across the board. This week's Expert View, from Sinead McGlone, director of quality management at industry analyst IQVIA, considers the regulatory implications.
The pace of innovation and digital transformation is increasing in the life science industry, particularly regarding regulatory compliance.
As a result of the pandemic, when new age technologies were used to rapidly develop COVID-19 vaccines, treatments and tests, the use of automation and artificial intelligence to also optimize pharmacovigilance (PV) and regulatory compliance operations is on the rise.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze